Recently, the FDA approved an investigational new drug (IND) application for ‘1104, a first-in-class peptide for the treatment of eosinophilic esophagitis (EoE). Now, Revolo Biotherapeutics will move forward to investigate ‘1104 in a Phase 2 trial.

‘1104 for EoE

‘1104 is intended for the treatment of allergic diseases, such as EoE. It’s unique due to its ability to stop the characteristic inflammation of the disease without impacting the immune system’s functions; it works upstream in the inflammation-driving practice.

Previous research has demonstrated ‘1104’s ability to lower the levels of eosinophils, inflammatory cytokines, neutrophils, and lymphocytes. At the same time, it increased levels of regulatory T cells. This data is very promising, and it holds the potential to revolutionize care for EoE and other allergic diseases.

Medical professionals and patients alike are excited for the upcoming Phase 2 trial; hopefully, it will lead to another treatment option.

About EoE

Eosinophilic esophagitis (EoE) is a digestive system disorder in which there are high levels of eosinophils in the esophagus. High amounts of these white blood cells typically accumulate when one is exposed to an allergen. Medical professionals have also found that some affected individuals have a high expression of the eotaxin-3 gene, so there may be a genetic component to this condition as well. Regardless of the cause, symptoms include difficulty swallowing, malnutrition, a poor appetite, nausea, vomiting, stomach pain, poor growth, weight loss, and food getting stuck in the throat. In terms of treatment, a change in diet has been proven to greatly improve symptoms. Doctors advise that patients avoid milk, fish, eggs, nuts, soy, and wheat. If one has a very severe case, they may need a liquid diet or steroids to reduce inflammation.

Find the source article here.